ライフサイエンスコーパス: HTLV

1 HTLV-1 and HTLV-2 encode auxiliary proteins that play im

2 HTLV-1 cell-to-cell transmission is dependent on the rel

3 HTLV-1 clonality studies revealed the presence of multip

4 HTLV-1 encodes a protein from the antisense strand of it

5 HTLV-1 infection can lead to many different and often fa

6 HTLV-1 is a complex retrovirus that causes two distinct

7 HTLV-1 is now known to infect at least 4-10 million peop

8 HTLV-1 orf-I encodes two proteins, p8 and p12, whose fun

9 HTLV-1 prevalence was 8.6% (23/269) in individuals with

10 HTLV-1 prevalences for children and adults were 6.1% and

11 HTLV-1 primarily infects T cells and initially spreads w

12 HTLV-1 serology was performed by Western blot on plasma

13 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lym

14 HTLVs arose from interspecies transmission between nonhu

15 ss the infectivity of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/SCID/gam

16 e of human T-cell lymphotropic virus type 1 (HTLV-1) and hepatitis B virus (HBV) coinfection is high

17 such as human T-cell leukemia virus type 1 (HTLV-1) and HIV-1.

18 s of human T-cell lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1),

19 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

20 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

21 against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could b

22 PORTANCE Human T-cell leukemia virus type 1 (HTLV-1) causes a variety of diseases, ranging from a fat

23 Human T-lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukemia, a disease commonly

24 Human T-cell leukemia virus type 1 (HTLV-1) causes multiple pathological effects, ranging fr

25 trovirus human T-cell leukemia virus type 1 (HTLV-1) contains identical DNA sequences, known as long

26 Human T-cell leukemia virus type 1 (HTLV-1) expression depends on the concerted action of Ta

27 ssion, of human T lymphotropic virus type 1 (HTLV-1) expression, while YY1 down-regulation reduces HT

28 ple, human T-cell lymphotropic virus type 1 (HTLV-1) has been reported to infect up to 25 million peo

29 from Human T-cell Lymphotropic Virus Type 1 (HTLV-1) infection to lethal Adult T-cell Leukaemia (ATL)

30 Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus and the most oncogenic path

31 Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus, and, as such, its genome become

32 Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that induces a fatal

33 ith human T-cell lymphotrophic virus type 1 (HTLV-1) is associated with shorter survival for adults a

34 cture of human T-cell leukemia virus type 1 (HTLV-1) is poorly characterized.

35 Human T-cell lymphotropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tro

36 Human T cell leukemia virus type 1 (HTLV-1) is the ethological agent of adult T cell leukemi

37 Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemi

38 that the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax induces an epigenetic-dependent

39 able for human T-cell leukemia virus type 1 (HTLV-1) particle biogenesis.

40 Human T-cell leukemia virus type 1 (HTLV-1) propagates within and between individuals via ce

41 Human T cell leukemia virus, type 1 (HTLV-1) replication and spread are controlled by differe

42 The human T-cell leukaemia virus type 1 (HTLV-1) subtype c is endemic to central Australia.

43 Human T cell leukemia virus type 1 (HTLV-1), also known as human T lymphotropic virus type 1

44 Tax from human T-cell leukemia virus type 1 (HTLV-1), an etiological factor that causes adult T-cell

45 Human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia and T-cell lymp

46 Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is an inflammatory c

47 Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

48 en in 22 human T cell leukemia virus type 1 (HTLV-1)-infected individuals by assessing their infectiv

49 0 million human T-lymphotropic virus type 1 (HTLV-1)-infected people, and many of them will develop s

50 aused by human T-cell leukemia virus type 1 (HTLV-1).

51 h is human T-cell lymphotropic virus type 1 (HTLV-1).

52 and human T cell lymphotropic virus type 1 (HTLV-1).

53 Human T-cell leukemia virus type 1 (HTLV-I) is associated with adult T-cell leukemia (ATL),

54 Human T-lymphotropic virus type-1 (HTLV-1) persists within hosts via infectious spread (de

55 aused by human T-cell leukemia virus type-1 (HTLV-1).

56 trovirus human T-cell leukemia virus type-1 (HTLV-1).

57 -kappaB by the human T-lymphotropic virus 1 (HTLV-1) oncoprotein Tax immediately triggers a host sene

58 ies, including human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

59 like the distantly related lentivirus HIV-1, HTLV-1 causes disease in only 5-10% of infected people,

60 everal regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene constitu

61 a panel of Gag proteins with chimeric HIV-1/HTLV-1 CA domains.

62 ously thought (typically between 104 and 105 HTLV-1+ T cell clones in the body of an asymptomatic car

63 Five subjects with HAM and 2 HTLV-1 asymptomatic carriers were studied.

64 uman T cell lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2) and bovine leukaemia virus (BLV).

65 Human T-lymphotropic viruses type 1 and 2 (HTLV-1/2) are prevalent in endemic clusters globally, an

66 l leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviruses that have distin

67 l leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviruses that transform T

68 Mother-to-child infection was excluded in 6 HTLV-1-infected bitten individuals.

69 (C. agilis in one case) were infected with a HTLV-1 subtype F strain very similar to the STLV-1 strai

70 ersists during chronic infection, even after HTLV-1 proviral load has reached its set point, and we e

71 d retained robust oncolytic activity against HTLV-1 actuated ATL cells.

72 ortant aspects of the human response against HTLV-1 and could be an important tool for the developmen

73 e evaluated as privileged structures against HTLV-1 protease (HTLV-1 PR).

74 t be useful for developing a vaccine against HTLV-1.

75 raction of the brain stem was reduced in all HTLV-1-infected patients compared with controls (P < 0.0

76 We found that stable expression of an HTLV-1 accessory protein, HTLV-1 bZIP factor (HBZ), in J

77 We show that an HTLV-1-infected cell line (MT-2) and naturally infected

78 ave used cryo-electron tomography to analyze HTLV-1 particle morphology.

79 have shown for the first time that HIV-1 and HTLV-1 Gag domains outside the CA (e.g., matrix and nucl

80 HTLV-1 and HTLV-2 encode auxiliary proteins that play important rol

81 Functional comparisons of HTLV-1 and HTLV-2 proteins provide a better understanding about how

82 lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2) and bovine leukaemia virus (BLV).

83 cal agent of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesi

84 V-1 infection is associated with disease and HTLV-2 infection is not.

85 Associations between specific diseases and HTLV-1 status were determined using logistic regression,

86 6.8 nM and 8.5 nM for HIV gene, HBV gene and HTLV-I gene, respectively.

87 prevalent in endemic clusters globally, and HTLV-1 infects at least 5 to 10 million individuals.

88 viously, our group found that HTLV-1 HBZ and HTLV-2 APH-2 had distinct effects in vivo and hypothesiz

89 Iatrogenic transmission of HCV and HTLV-1 occurred in mid-20th century Kinshasa, at the sam

90 B'-PP2A and HTLV-1 IN display nuclear co-localization, and the B' su

91 ty of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/SCID/gamma(C) (-/-) c-ki

92 assay was evaluated and did not detect anti-HTLV-1/2 IgG in 14% (5/36) of OF specimens from seroposi

93 A was developed and validated to detect anti-HTLV-1/2 IgG in OF.

94 an T-cell leukemia virus (HTLV; now known as HTLV-1) produced by a T-cell line from a lymphoma patien

95 s similarities to human retroviruses such as HTLV-1, the development of an effective treatment would

96 ommunity recruitment and blinded assessment, HTLV-1 infection was strongly associated with pulmonary

97 e receptor expression did not differ between HTLV-1-infected and uninfected individuals.

98 No associations were found between HTLV-1 and any assessed clinical condition among childre

99 ces may affect how HTLV-1 causes disease but HTLV-2 generally does not.

100 eukemia (ATL), a T-cell malignancy caused by HTLV-1 infection.

101 malignant or inflammatory diseases caused by HTLV-1.

102 coinfection by HTLV-1 is associated with shorter survival for adults an

103 vent the senescence and G1 arrest induced by HTLV-1 Tax and vFLIP, respectively.

104 We matched 149 patients co-infected by HTLV-1 (cases) by age at HIV diagnosis and gender to equ

105 rm that hunters in Africa can be infected by HTLV-1 that is closely related to the strains circulatin

106 ice) were highly susceptible to infection by HTLV-1(WT), with a syndrome characterized by the rapid p

107 rt the notion that infection of monocytes by HTLV-1 is likely a requisite for viral persistence in hu

108 ATL is preceded by decades of chronic HTLV-1 infection, and the tumors carry both somatic muta

109 ishes the infectivity of the molecular clone HTLV-1(p12KO) In rabbits, HTLV-1(p12KO) is infective and

110 In contrast, HTLV-2, which expresses Tax2, is non-leukemogenic.

111 Together with their simian counterparts, HTLVs form the primate T-lymphotropic viruses.

112 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

113 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

114 As a first step in designing an effective HTLV-1 vaccine, we defined the CD8(+) and CD4(+) T cell

115 st defense responses, which may help explain HTLV-1-related pathogenesis and oncogenesis.

116 The MT-4 human T-cell line expresses HTLV-1 Tax and is permissive for replication of an HIV-1

117 Higher cerebrospinal fluid HTLV-1 proviral load (p = 0.01) was associated with thin

118 Blood was drawn for HTLV-1 serology and proviral load (PVL).

119 Risk factors for HTLV-1 seropositivity included intravenous injections at

120 mice may provide a window of opportunity for HTLV-1 replication and the selection of viral variants w

121 PCR was carried out for HTLV-1 provirus on buffy-coat DNAs.

122 s have been described, such a regulation for HTLV-1 has not been reported.

123 The use of OF serological screening for HTLV-1/2 infection could facilitate large-scale seroprev

124 s) are among the first potential targets for HTLV-1.

125 There is no effective treatment for HTLV-1, and the osteolytic mechanisms are not fully unde

126 e development of a therapeutic treatment for HTLV-1-mediated disease.

127 Free HTLV-1 virions are poorly infectious, so infection of T

128 e for Human Retrovirology (n = 131) and from HTLV-1/2-uninfected individuals (n = 64).

129 detectable in most primary lymphocytes from HTLV-2-infected patients.

130 All three monocyte subsets sorted from HTLV-1-infected individuals were positive for viral DNA,

131 fs of five retroviruses of different genera: HTLV-1, HIV-1, murine leukaemia virus (MLV), avian sarco

132 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus type 1) is a chroni

133 racteristics of individuals with low or high HTLV-1 proviral load (pVL), symptomatic disease, and the

134 ed to survival time in a large cohort of HIV-HTLV-1 co-infected and HIV mono-infected patients on cAR

135 with survival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on co

136 ins provide a better understanding about how HTLV-1 infection is associated with disease and HTLV-2 i

137 these functional differences may affect how HTLV-1 causes disease but HTLV-2 generally does not.

138 Human T-cell lymphotropic virus type I (HTLV-1) is an oncogenic retrovirus considered to be the

139 The human T-cell lymphotropic virus type I (HTLV-1) Tax transactivator initiates transformation in a

140 gene and human T-lymphotropic virus type I (HTLV-I) gene.

141 with human T-cell lymphotropic virus type I (HTLV-I) infection, and multiple sclerosis (MS), an infla

142 a defined capsid core, which likely impacts HTLV-1 particle infectivity.

143 of miR-124a, is constitutively activated in HTLV-I-transformed cells and ATL cells, and activating S

144 ing factor for dysregulation of autophagy in HTLV-1-transformed T cells and Tax-immortalized CD4 memo

145 are often the only viral genes expressed in HTLV-infected T cells.

146 Among several regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene

147 CX3CR1 in classical monocytes were higher in HTLV-1-infected individuals than uninfected individuals;

148 However, in HTLV-1-infected T cells, knockdown of HBZ expression did

149 assical patrolling monocytes is increased in HTLV-1-infected individuals, and they have increased exp

150 w is that infectious spread is negligible in HTLV-1 persistence beyond early infection.

151 hting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

152 otein-encoding open reading frames (ORFs) in HTLV-3, the latest HTLV to be discovered, is unknown.

153 sence of ORFs encoding auxiliary proteins in HTLV-3 or STLV-3 genomes was unknown.

154 nflammation in the spinal cord, resulting in HTLV-1-associated myelopathy/tropical spastic paraparesi

155 ell-to-cell transmission, a critical step in HTLV-1 transmission and pathogenesis.

156 -mediated inflammatory conditions, including HTLV-1-associated myelopathy/tropical spastic paraparesi

157 kat cells (used as effector cells) increases HTLV-1 infection.

158 s have important implications for infectious HTLV-1 spread, particularly in the context of cell-to-ce

159 this study, we found that miR-28-3p inhibits HTLV-1 virus expression and its replication by targeting

160 ata provide further mechanistic insight into HTLV-1-mediated subversion of cellular host defense resp

161 nsfected with Rex-wild-type and Rex-knockout HTLV-1 molecular clones using splice site-specific quant

162 reading frames (ORFs) in HTLV-3, the latest HTLV to be discovered, is unknown.

163 Despite low prevalence, many HTLV-1-infected patients who do not fulfill criteria for

164 tated in ATL than did high-risk, age-matched HTLV-1 carriers who remained ATL-free after a median of

165 ntegral component of the intasome to mediate HTLV-1 integration.

166 Many of the ~20 million HTLV-1 infected people will develop severe leukaemia or

167 Moreover, HTLV-1 infection was linked to bite severity.

168 The Murex HTLV I+II commercial assay was evaluated and did not det

169 and we estimate that between 100 and 200 new HTLV-1 clones are created and killed every day.

170 protective role of miR-28-3p against de novo HTLV-1 infection.

171 at Gag proteins with a chimeric HIV-1 CA NTD/HTLV-1 CA CTD did not result in Gag oligomerization rega

172 ent high-throughput data on the abundance of HTLV-1 clones, and recent estimates of HTLV-1 clonal div

173 the differences in transforming activity of HTLV-1 and -2.

174 tropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tropical spastic paraparesi

175 Analysis of HTLV-1 integrations in two cell lines, HuT 102 and MJ, i

176 lassical monocytes was lower in the blood of HTLV-1-infected individuals than in that of uninfected i

177 The brains of HTLV-1-infected patients, with and without HAM but no cl

178 controls [HCs], 17 asymptomatic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS

179 Functional comparisons of HTLV-1 and HTLV-2 proteins provide a better understandin

180 gy to deregulate autophagy in the context of HTLV-1 transformation of T cells.

181 However, the technology for discovery of HTLV and acknowledgment of the existence of pathogenic h

182 ce of HTLV-1 clones, and recent estimates of HTLV-1 clonal diversity that are substantially higher th

183 ance, confirming the polyclonal expansion of HTLV-1-infected cells in vivo HTLV-1(p12KO) infection in

184 significant increase in clonal expansion of HTLV-1-infected lymphocytes in coinfected asymptomatic i

185 CD4:CD8 ratio inflation is a feature of HTLV-1 infection, whereas enhanced CD4+ T cell maturatio

186 ase class III resulted in impaired growth of HTLV-1-transformed T cells, indicating a critical role o

187 Given the low incidence of HTLV-1-associated diseases among carriers, such cellular

188 igh prevalence might reduce the incidence of HTLV-1-induced disease.

189 evidence that the known poor infectivity of HTLV-1 particles may correlate with HTLV-1 particle popu

190 hich significantly revisits our knowledge of HTLV-1 pathogenesis and other NF-kappaB-related diseases

191 osure and was associated with high levels of HTLV-1 DNA in blood and the expansion of CD4(+) CD25(+)

192 er with prior findings in a macaque model of HTLV-1 infection, support the notion that infection of m

193 unately, there are very few animal models of HTLV-1 infection useful for testing vaccine approaches.

194 ich in turn is correlated with the number of HTLV-1-infected clones, which are created by de novo inf

195 HIV diagnosis and gender to equal number of HTLV-negative patients (controls).

196 HIV diagnosis and sex, to an equal number of HTLV-uninfected persons (controls).

197 s in the natural history and pathogenesis of HTLV-1 infection.

198 se humanized mice mirrors the early phase of HTLV-1 infection in humans, providing a useful model to

199 c activity when expressed in the presence of HTLV-I Tax, mutated p53 R276H, or c-Myc F138C found in h

200 Thus, the process of HTLV-1 cell-to-cell transmission within the host helps i

201 n, while both Tax-3 and antisense protein of HTLV-3 (APH-3) promoted cellular transformation.

202 bjective measures of gait, quantification of HTLV-1 proviral load in peripheral blood mononuclear cel

203 ar CD4 cell count at baseline, regardless of HTLV status.

204 YY1 binds to the R region of HTLV-1 RNA in vitro and in vivo, leading to increased tr

205 The risk of HTLV-1-associated malignancy and inflammatory disease is

206 ideal for further examination of the role of HTLV-1 Tax in osteolytic tumor formation and the develop

207 Therefore, infectious spread of HTLV-1 within the T-cell population may be one underlyin

208 In the first study of HTLV-1 disease associations based on community recruitme

209 ammatory myelopathy occurring in a subset of HTLV-1-infected individuals.

210 rge-scale, community-based, health survey of HTLV-1 and its disease associations in this setting.

211 ppaB activation by the viral oncogene Tax of HTLV-1.

212 The p9 localization is similar to that of HTLV-1 p12 and induced a strong decrease in the calretic

213 icate that YY1 is a potent transactivator of HTLV-1 gene expression acting via binding viral RNA, rat

214 acts also facilitate DC-mediated transfer of HTLV-1 to autologous CD4(+) T cells.

215 us Australian populations, but its impact on HTLV-1 has not been described.

216 s can be used to quantify and study HIV-1 or HTLV-1 cell-mediated infection in a simple one-step tran

217 Here we demonstrate that ATL-derived or HTLV-1-transformed cells are dependent on continuous Tax

218 ia/lymphoma and tropical spastic paraparesis/HTLV-1-associated myelopathy in about 5% of infected ind

219 Clones of premalignant HTLV-1-infected cells bearing known driver mutations wer

220 ivileged structures against HTLV-1 protease (HTLV-1 PR).

221 Here we found that the viral protein HTLV-1 bZIP factor (HBZ) promotes infectivity.

222 e expression of an HTLV-1 accessory protein, HTLV-1 bZIP factor (HBZ), in Jurkat T cells increases ho

223 ic processes, fitted to previously published HTLV-1 clonal diversity estimates.

224 he molecular clone HTLV-1(p12KO) In rabbits, HTLV-1(p12KO) is infective and persists efficiently.

225 xpression, while YY1 down-regulation reduces HTLV-1 expression.

226 ad similar CD4 count at baseline, regardless HTLV status.

227 The human-pathogenic retroviruses HTLV-1 and HIV-1 can be transmitted more efficiently in

228 ma specimens were obtained from seropositive HTLV-1/2-infected patients attending the National Centre

229 ared the effects of HBZ and APH-2 on several HTLV-relevant cellular pathways, including the TGF-beta

230 The 2 groups had a similar HTLV-1 proviral load, but there was a significant increa

231 r B' incapable of binding to and stimulating HTLV-1 and -2 IN strand transfer activity.

232 ory mechanism may be important for long-term HTLV-1 infection.

233 We conclude that HTLV-1/HBV coinfection may predispose to HTLV-1-associat

234 sion electron microscopy to demonstrate that HTLV-1 particles produced from a distinct chronically in

235 in Japan, provided conclusive evidence that HTLV was the cause of this disease.

236 Previously, our group found that HTLV-1 HBZ and HTLV-2 APH-2 had distinct effects in vivo

237 In addition, we found that HTLV-1, subtype 1A isolates corresponding to the Japanes

238 We show here that HTLV-1 may be able to successfully infect the T cells an

239 These studies indicated that HTLV-I-transformed and ATL cells, but not normal periphe

240 Importantly, we revealed that HTLV-1 bZIP factor (HBZ) protein which is expressed in a

241 These data show that HTLV-1-infected T-cell clones carrying key oncogenic dri

242 The HTLV genome antisense-strand genes hbz and aph-2 are oft

243 The HTLV-1 particle structure is still poorly understood, an

244 The HTLV-1 R sequence alone is sufficient to provide YY1 res

245 All the HTLV-1-positive hunters bitten by a gorilla or chimpanze

246 s highly divergent and was designated as the HTLV-4 subtype-b prototype.

247 Mice expressing the HTLV-1 oncogene Tax, driven by the human granzyme B prom

248 antisense strand of its proviral genome, the HTLV-1 basic leucine zipper factor (HBZ), which inhibits

249 t mapped not to YY1 DNA-binding sites in the HTLV-1 LTR but to the R region.

250 To more clearly define the roles of the HTLV-1 CA amino-terminal domain (NTD) and CA CTD in part

251 articles, highlighting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

252 ing experimental system for the study of the HTLV-1 particle structure.

253 critical infection-related functions of the HTLV-1 regulatory protein Tax.

254 The antisense strand of the HTLV-2 proviral genome also encodes a protein termed APH

255 CTD, but the HIV-1 CA NTD cannot replace the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains

256 In this study, the HTLV-1 capsid amino-terminal domain was found to provide

257 e constitute a useful model for studying the HTLV-1-associated polyclonal proliferation of CD4(+) T c

258 observations support the conclusion that the HTLV-1 CA NTD can functionally replace the HIV-1 CA CTD,

259 place the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains provide distinct contributions to G

260 se cryo-electron microscopy to visualize the HTLV-1 intasome at 3.7- angstrom resolution.

261 Furthermore, chimeric Gag proteins with the HTLV-1 CA NTD produced particles phenotypically similar

262 inical examination by a physician blinded to HTLV-1 status, clinical records and spirometry results.

263 y structures of two representatives bound to HTLV-1 PR were determined, and the structural basis of t

264 rall results suggest that HBZ contributes to HTLV-1 infectivity.IMPORTANCE Human T-cell leukemia viru

265 virus type 3 (STLV-3) is almost identical to HTLV-3.

266 hat HTLV-1/HBV coinfection may predispose to HTLV-1-associated malignant disease.

267 type 1 (STLV-1), a virus closely related to HTLV-1, in olive baboons (Papio anubis).

268 d in resting T cells, which are resistant to HTLV-1 infection, we investigated a potential protective

269 ttributed to the cellular immune response to HTLV-1-infected lymphocytes.

270 produced particles phenotypically similar to HTLV-1 immature particles, highlighting the importance o

271 ase in the calreticulin signal, similarly to HTLV-1 p12.

272 ibutions of infectious and mitotic spread to HTLV-1 persistence are unknown, and will determine the e

273 uninfected target T cells and then transfer HTLV-1 virus particles to the target cells.

274 to assess the infectivity of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/

275 Human T-cell leukemia virus (HTLV) type 1, the etiological agent of adult T-cell leuk

276 r mutations for human T-cell leukemia virus (HTLV)-associated adult T-cell leukemia lymphoma (ATLL) c

277 acterization of human T-cell leukemia virus (HTLV; now known as HTLV-1) produced by a T-cell line fro

278 associated with human T lymphotropic virus (HTLV) infection.

279 ica identified 2 human T-lymphotropic virus (HTLV)-4-infected individuals.

280 cination against human T lymphotropic virus (HTLV).

281 s (HCV) and human T-cell lymphotropic virus (HTLV-1) can be used to investigate past iatrogenic trans

282 re infected with human T lymphotropic virus (HTLV-1).

283 l expansion of HTLV-1-infected cells in vivo HTLV-1(p12KO) infection in a bone marrow-liver-thymus (B

284 25.9%) were HCV seropositive; 26 (3.1%) were HTLV-1-seropositive.

285 A vaccine is urgently needed in areas where HTLV-1 is endemic.

286 These data suggest a model whereby HTLV-1 infection augments the number of classical monocy

287 rmalities were more common among adults with HTLV-1 infection.

288 tly impact the global burden associated with HTLV infections.

289 We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis and sex, to an eq

290 ivity of HTLV-1 particles may correlate with HTLV-1 particle populations containing few virus particl

291 correlation of the TCR clonal expansion with HTLV-I proviral load.

292 2 groups of Indigenous adults infected with HTLV-1, either alone or coinfected with HBV.

293 hocytic cell lines chronically infected with HTLV-1, particularly the MT-2 cell line, which harbors t

294 ysregulation of CD4(+) T cells infected with HTLV-1.

295 lops in 2 to 5% of individuals infected with HTLV-1.

296 FACT proteins also interfere with HTLV-1 Tax-LTR-mediated transcription and viral latency,

297 naive CD4+ T cells correlated inversely with HTLV-1 pVL (rs = -0.344, P = .026).

298 unosuppressive therapy, 38 women living with HTLV-1 infection, at a median age of 59 (52-68) years, w

299 y of an asymptomatic carrier or patient with HTLV-1-associated myelopathy/tropical spastic paraparesi

300 ion and disease progression in patients with HTLV-1-associated inflammatory diseases.

301 to that of cells isolated from patients with HTLV-I-associated adult T-cell leukemia or with progeria

302 ne responses all parallel what are seen with HTLV infection of humans.